Dimensional Fund Advisors’s PharmaCyte Biotech PMCB Stock Holding History

Dimensional Fund Advisors’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,299	Closed	-$22.3K	–	3329
2025 Q2	$22.3K	Hold	20,299	–	–	﹤0.01%	3267
2025 Q1	$25.4K	Sell	20,299 -6,542	-24%	-$10.6K	﹤0.01%	3292
2024 Q4	$41.6K	Sell	26,841 -760	-3%	-$1.31K	﹤0.01%	3303
2024 Q3	$52.7K	Buy	27,601 +2,005	+8%	+$3.73K	﹤0.01%	3293
2024 Q2	$50.2K	Buy	25,596 +1,033	+4%	+$2.23K	﹤0.01%	3316
2024 Q1	$58.2K	Sell	24,563 -4,744	-16%	-$10.3K	﹤0.01%	3325
2023 Q4	$63.3K	Hold	29,307	–	–	﹤0.01%	3332
2023 Q3	$61.5K	Buy	29,307 +4	+0%	+$10	﹤0.01%	3365
2023 Q2	$83.8K	Hold	29,303	–	–	﹤0.01%	3348
2023 Q1	$85.3K	Buy	+29,303	New	+$86.1K	﹤0.01%	3324

Other funds holding PMCB

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $187M AUM 179.87% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Dimensional Fund Advisors's PMCB Position: Q3 2025 in Review

Dimensional Fund Advisors sold out of PharmaCyte Biotech (PMCB) in Q3 2025, closing a stake of 20,299 shares — an estimated $22.3K sold.

Dimensional Fund Advisors first reported a position in PMCB in Q1 2023 and held it in 10 quarters. The position peaked at $85.3K in Q1 2023. 23 funds tracked by Wall St. Rank hold PMCB as of Q3 2025.

Dimensional Fund Advisors reported no remaining PharmaCyte Biotech position as of Q3 2025 after selling out during the quarter.
Dimensional Fund Advisors sold 20,299 PharmaCyte Biotech shares in Q3 2025, an estimated $22.3K.
Dimensional Fund Advisors first reported a position in PharmaCyte Biotech in Q1 2023 and held it in 10 quarters.
Dimensional Fund Advisors's PharmaCyte Biotech position peaked at $85.3K in Q1 2023.
23 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2025.

Based on Dimensional Fund Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.